FDA grants RMAT status for BlueRock’s Parkinson’s therapy

31 May 2024
www.pharmaceutical-technology.com
Phase 1Cell TherapyGene Therapy
FDA grants RMAT status for BlueRock’s Parkinson’s therapy
Preview
Source: Pharmaceutical Technology
Bemdaneprocel is created to replace the dopamine-producing neurons lost due to Parkinson’s disease. Credit: Annick Vanblaere from Pixabay.
FDA grants RMAT status for BlueRock’s Parkinson’s therapy
Preview
Source: Pharmaceutical Technology
The US Food and Drug Administration (FDA) has granted a regenerative medicine advanced therapy (RMAT) designation for BlueRock Therapeutics’ investigational cell therapy bemdaneprocel (BRT-DA01) for Parkinson’s disease.
Recommended Buyer's Guides
FDA grants RMAT status for BlueRock’s Parkinson’s therapy
Preview
Source: Pharmaceutical Technology
Buyer's Guide
Leading Guide to Packaging Materials, Containers and Containment Services for the Pharmaceutical Industry
FDA grants RMAT status for BlueRock’s Parkinson’s therapy
Preview
Source: Pharmaceutical Technology
Buyer's Guide
Top Guide for Drug Delivery Systems
BlueRock is a wholly owned independently operated Bayer subsidiary.
Bemdaneprocel is claimed to be the most clinically advanced cell therapy for Parkinson’s disease treatment in the US.
The therapy is created to replace the dopamine-producing neurons lost in the course of the disease.
It was assessed in the multi-site, multicentre, non-randomised, open-label, non-controlled study.
See Also:Dupixent gets closer to EU approval as the FDA delays its decision on COPD
FDA grants RMAT status for BlueRock’s Parkinson’s therapy
Preview
Source: Pharmaceutical Technology
Bristol Myers Squibb’s Breyanzi gains FDA approval for lymphoma
FDA grants RMAT status for BlueRock’s Parkinson’s therapy
Preview
Source: Pharmaceutical Technology
The trial involved 12 subjects diagnosed with Parkinson’s disease who underwent surgical transplantation of bemdaneprocel cells into the post-commissural putamen bilaterally, followed by a one-year immunosuppression regimen.
Data from the trial, announced in March 2024, indicated that bemdaneprocel was well tolerated and did not present major safety issues up to 18 months post-treatment.
Furthermore, an increase in the F-DOPA PET imaging signal was observed after the cessation of immune suppression therapy at 12 months, suggesting that the transplanted cells survive and engraft in the brain.
The RMAT designation is managed by the FDA’s Center for Biologics, Evaluation and Research (CBER). It is specifically for investigational regenerative therapies, including cell therapies, aimed at treating, modifying, reversing or curing serious ailments.
Therapies granted RMAT status can benefit from expedited development review and development planning guidance from senior CBER managers.
This status also facilitates early discussions about possible surrogate endpoints and strategies to support accelerated approval and satisfy post-approval needs.
BlueRock Therapeutics president and CEO Seth Ettenberg stated: “We are excited about the positive data from the bemdaneprocel Phase I clinical trial and believe it has great potential to help patients living with Parkinson’s disease regain functions they have lost to the disease.
“Now with this RMAT designation in hand, we look forward to closely collaborating with the FDA to ready this programme for Phase II clinical studies.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline
The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.
Thank you.You will receive an email shortly. Please check your inbox to download the Whitepaper.
FDA grants RMAT status for BlueRock’s Parkinson’s therapy
Preview
Source: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.